AttendMe Owl Logo
AttendMe
Evidence Evolution
AnesthesiologyAnesthesiology

How This Evidence Evolved

Enhanced Recovery After Surgery (ERAS)

From traditional recovery to multimodal fast-track

1995-20242.1

Timeline

Kehlet Fast-Track
2002
LAFA Trial
2011
EnROL
2014
RELIEF
2018
ERAS Society Guidelines
2018
ASA Enhanced Recovery Advisory 2023
2023
Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

Traditional perioperative care in the 1990s was characterised by prolonged fasting, mechanical bowel preparation, routine nasogastric tubes, bed rest, and liberal opioid analgesia — practices based on tradition rather than evidence. Henrik Kehlet, a Danish surgeon, published a series of landmark papers in the late 1990s articulating a revolutionary concept: that the surgical stress response could be attenuated through a multimodal, evidence-based bundle of perioperative interventions. His 1997 Lancet paper outlined the 'fast-track surgery' paradigm, demonstrating that combining regional anaesthesia, early nutrition, early mobilisation, and minimally invasive technique could achieve discharge after colonic resection in 2-3 days rather than the conventional 7-10 days. This was not a single intervention but a philosophy — and it challenged every specialty to re-examine its perioperative dogma.
Proof

Landmark RCTs and pivotal trials that established the evidence base

The ERAS Society, founded in 2010, formalised Kehlet's principles into structured, procedure-specific protocols supported by systematic reviews. The LAFA trial (2011) provided randomised evidence that ERAS combined with laparoscopy achieved faster recovery than traditional open surgery with conventional care in colorectal resection. The EnROL trial (2012) demonstrated that ERAS protocols reduced length of stay after liver resection without increasing complications. Multiple meta-analyses confirmed that ERAS programmes consistently reduced hospital stay by 2-3 days and complication rates by 30-50% across surgical specialities including colorectal, urological, gynaecological, and thoracic surgery. Importantly, these benefits were achieved without increasing readmission rates — addressing the primary concern that 'faster' meant 'premature.'
Extension

Follow-up studies, subgroup analyses, and real-world validation

ERAS has expanded far beyond colorectal surgery into virtually every surgical specialty. Procedure-specific ERAS guidelines now exist for cardiac, thoracic, hepatobiliary, pancreatic, gynaecological, urological, and orthopaedic surgery. A critical evolution has been the integration of opioid-sparing multimodal analgesia — combining regional anaesthesia, acetaminophen, NSAIDs, gabapentinoids, ketamine, and local infiltration to minimise opioid use. The RELIEF trial (2018) challenged the traditional liberal fluid paradigm within ERAS, showing no benefit of restrictive versus moderately liberal fluid therapy in abdominal surgery and suggesting that the goal-directed approach is more important than absolute restriction. ERAS compliance has emerged as a key quality metric, with evidence showing a dose-response relationship between protocol adherence and outcomes.
Guidelines

Integration into clinical practice guidelines and recommendations

The ERAS Society has published over 20 procedure-specific consensus guidelines, each based on systematic reviews of individual pathway elements. The 2018 ERAS guidelines for colorectal surgery represent the most mature pathway, covering preoperative counselling, carbohydrate loading, avoidance of bowel preparation, short-acting anaesthetic agents, multimodal opioid-sparing analgesia, early oral nutrition, and early mobilisation. ASA and ESA perioperative guidelines now incorporate ERAS principles. The WHO has endorsed ERAS as a patient safety initiative. National surgical quality programmes in multiple countries have adopted ERAS compliance as a reportable quality metric.
ERAS Society Colorectal Guidelines 2018

Multimodal evidence-based pathway: carbohydrate loading, avoidance of routine bowel prep, opioid-sparing analgesia, early nutrition, early mobilisation; strong recommendation across 24 elements

ASA Practice Advisory on Enhanced Recovery 2023

Recommend implementation of ERAS pathways with multimodal analgesia, goal-directed fluid therapy, and early mobilisation across surgical specialties

Now

Current standard of care and ongoing research directions

ERAS is now the standard of care for elective surgery in high-income countries, with implementation varying widely by institution and specialty. The greatest challenge is not the evidence base but implementation science — achieving and sustaining high compliance rates with all pathway elements. Data from ERAS Interactive Audit System shows that compliance above 80% is associated with significantly better outcomes, yet average compliance hovers around 60-70% at many centres. The opioid crisis has given renewed urgency to the multimodal analgesia components. Current frontiers include prehabilitation (optimising patients weeks before surgery), personalised pathways using wearable monitoring, AI-driven prediction of readiness for discharge, and extension of ERAS principles into emergency surgery where recovery optimisation is arguably even more impactful.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

What are the key components of an ERAS protocol?+
ERAS protocols typically include 20-25 evidence-based elements grouped into three phases: preoperative (patient education, carbohydrate loading, avoidance of prolonged fasting, no routine bowel prep), intraoperative (short-acting anaesthetics, minimally invasive approach where possible, goal-directed fluid therapy, multimodal analgesia, normothermia), and postoperative (early oral nutrition, early mobilisation, opioid-sparing analgesia, scheduled PONV prophylaxis, early removal of drains and catheters).
Does ERAS increase readmission rates?+
No. This was the primary concern when ERAS was introduced, but multiple large studies and meta-analyses have consistently demonstrated that ERAS reduces length of stay without increasing readmission rates. In fact, some studies show reduced readmissions, likely because ERAS patients are better educated about their expected recovery trajectory and warning signs.
What is the anaesthesiologist's role in ERAS?+
The anaesthesiologist is central to ERAS success, responsible for: multimodal opioid-sparing analgesia (regional blocks, acetaminophen, NSAIDs, ketamine, gabapentinoids), goal-directed fluid therapy, PONV prophylaxis, normothermia maintenance, minimising long-acting agents that delay recovery, and perioperative risk stratification. The shift from opioid-centric to multimodal analgesia represents perhaps the largest practice change for anaesthesiologists.
Should fluid therapy be restrictive or liberal within ERAS?+
The RELIEF trial showed that restrictive fluid therapy did not improve outcomes and caused more acute kidney injury. Current ERAS guidelines recommend a goal-directed approach using stroke volume optimisation or similar dynamic parameters rather than fixed restrictive or liberal volumes. The key is avoiding both excess (tissue oedema, anastomotic complications) and deficit (organ hypoperfusion, AKI).

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Last reviewed: 3 April 2026